α-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease
| Autor: | Anja Schneider, Tanja Kraus, Walter Maetzler, Boguslawa Sadowski, Brit Mollenhauer, Markus A. Hobert, Björn Zapke, Anne Stuendl, Madhurima Chatterjee, Kathrin Brockmann, Christian Deuschle, Wiebke Moebius |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty Parkinson's disease Progressive supranuclear palsy 03 medical and health sciences Extracellular Vesicles 0302 clinical medicine α-synuclein pathology [Extracellular Vesicles] medicine Extracellular Humans ddc:610 plasma Dementia with Lewy bodies business.industry Vesicle Neurodegeneration Area under the curve Parkinson Disease medicine.disease 3. Good health pathology [Parkinson Disease] 030104 developmental biology Neurology alpha-Synuclein Biomarker (medicine) biomarker Neurology (clinical) Supranuclear Palsy Progressive business extracellular vesicles 030217 neurology & neurosurgery Biomarkers |
| Zdroj: | Movement disorders 36(11), 2508-2518 (2021). doi:10.1002/mds.28639 |
| DOI: | 10.1002/mds.28639 |
| Popis: | Background Extracellular vesicles are small vesicles that are released from many cells, including neurons. α-Synuclein has recently been described in extracellular vesicles derived from the central nervous system and may contribute to the spreading of disease pathology in α-synuclein-related neurodegeneration. Objectives We aimed to examine the potential diagnostic value of α-synuclein in plasma extracellular vesicles from patients with Parkinson's disease (PD). Methods Preanalytical variables were studied to establish an optimized assay for preparation of plasma extracellular vesicles and detection of extracellular vesicle-derived α-synuclein. Plasma samples were obtained from 2 independent cohorts. The Tubingen cohort contained 96 patients with PD, 50 patients with dementia with Lewy bodies, 50 patients with progressive supranuclear palsy (PSP), and 42 healthy controls; the Kassel cohort included 47 patients with PD, 43 patients with dementia with Lewy bodies, and 36 controls with secondary parkinsonian syndromes. Extracellular vesicles were prepared from total plasma by size exclusion chromatography and quantified by nanoparticle tracking analysis, α-synuclein content was measured by an electrochemiluminescence assay. Results α-Synuclein concentration in plasma extracellular vesicles provided the best discrimination between PD, dementia with Lewy bodies, PSP, and healthy controls, with an area under the curve of 0.804 (PD vs dementia with Lewy bodies), 0.815 (PD vs. PSP), and 0.769 (PD vs healthy controls) in the Tubingen cohort. Results were validated in the Kassel cohort. Conclusions The concentration of α-synuclein in plasma extracellular vesicles may serve as a potential diagnostic biomarker for PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|